文献速递慢性肾脏病肾小球疾病

Venglustat(一种新型葡萄糖神经酰胺合成酶抑制剂)用于快速进展型常染色体显性多囊肾病风险患者:双盲、安慰剂对照、2/3期随机临床试验主要结果

Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
PubMed 文献 · Am J Kidney Dis · 2022-12-17

STAGED-PKD是一项2阶段、多中心、双盲、随机、安慰剂对照2/3期研究,纳入快速进展风险的常染色体显性多囊肾病成人患者,第1阶段236例、第2阶段242例。预设期中无效性分析显示venglustat对18个月总肾脏体积年化变化率无影响,且第2阶段24个月eGFR斜率下降更快,研究因缺乏疗效提前终止。

要点

  • 在快速进展型ADPKD患者中,venglustat 8mg或15mg对总肾脏体积变化率无影响。
  • 第2阶段venglustat 15mg组24个月eGFR斜率下降更快。
  • 尽管血浆葡萄糖神经酰胺水平呈剂量依赖性下降,研究仍因缺乏疗效提前终止。

核心结论

  • 在快速进展型ADPKD患者中,venglustat 8mg或15mg治疗未改变总肾脏体积变化率,且eGFR下降更快,尽管血浆葡萄糖神经酰胺水平呈剂量依赖性下降。

研究设计与样本

  • STAGED-PKD为2阶段、多中心、双盲、随机、安慰剂对照2/3期研究。
  • 纳入基于Mayo Clinic影像分类为ADPKD 1C、1D或1E且eGFR 30-89.9mL/min/1.73m2的成人患者。
  • 第1阶段入组236例,第2阶段入组242例。
  • 第1阶段按1:1:1随机至venglustat 8mg、venglustat 15mg或安慰剂;第2阶段按1:1随机至venglustat 15mg(第1阶段确定的安全且耐受性良好的最高剂量)或安慰剂。

主要发现

  • 预设期中无效性分析显示,venglustat治疗对18个月总肾脏体积年化变化率无影响(第1阶段)。
  • 第2阶段venglustat 15mg组24个月eGFR斜率下降更快。
  • 研究因缺乏疗效提前终止。

关键数值与推荐

  • 主要终点:第1阶段18个月总肾脏体积变化率;第2阶段24个月eGFR斜率。
  • 次要终点:第1阶段18个月eGFR斜率、第2阶段总肾脏体积变化率,以及安全性和耐受性、疼痛、疲劳(第1和第2阶段)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 治疗后随访期短。
  • 研究结果的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the formation of multiple kidney cysts that leads to growth in total kidney volume (TKV) and progression to kidney failure. Venglustat is a glucosylceramide synthase inhibitor that has been shown to inhibit cyst growth and reduce kidney failure in preclinical models of ADPKD. STUDY DESIGN: STAGED-PKD was a 2-stage, multicenter, double-blind, randomized, placebo-controlled phase 2/3 study in adults with ADPKD at risk of rapidly progressive disease, who were selected based on Mayo Clinic imaging classification of ADPKD class 1C, 1D, or 1E and an estimated glomerular filtration rate (eGFR) of 30-89.9mL/min/1.73m2. SETTING & PARTICIPANTS: Enrollment included 236 and 242 patients in stages 1 and 2, respectively. INTERVENTIONS: In trial stage 1, the patients were randomized 1:1:1 to venglustat, 8mg; venglustat, 15mg; or placebo. In stage 2, the patients were randomized 1:1 to venglustat, 15mg (highest dose identified as safe and well tolerated in stage 1), or placebo. OUTCOMES: Primary end points were rate of change in TKV over 18 months in stage 1 and eGFR slope over 24 months in stage 2. Secondary end points were eGFR slope over 18 months (stage 1), rate of change in TKV (stage 2), and safety/tolerability, pain, and fatigue (stages 1 and 2). RESULTS: A prespecified interim futility analysis showed that venglustat treatment had no effect on the annualized rate of change in TKV over 18 months (stage 1) and had a faster rate of decline in eGFR slope over 24 months (stage 2). Due to this lack of efficacy, the study was terminated early. LIMITATIONS: The short follow-up period after the end of treatment and limited generalizability of the findings. CONCLUSIONS: In patients with rapidly progressing ADPKD, treatment with venglustat at either 8mg or 15mg showed no change in the rate of change in TKV and a faster rate of eGFR decline in STAGED-PKD despite a dose-dependent decrease in plasma glucosylceramide levels. FUNDING: This study was funded by Sanofi. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03523728.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Gansevoort RT, Hariri A, Minini P, et al. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2022. PMID: 36535535. doi:10.1053/j.ajkd.2022.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。